Collectively, the findings of this study identify new cellular and molecular effectors for HPRT-deficiency-mediated striatal dysfunctions and propose that the targeting DARPP-32/BDNF/TrkB may be a therapeutic strategy for LNS. This evidence concerns the gene BDNF and Lesch-Nyhan syndrome.